ストックスクリーナーアプリを入手
1.44
9.32%
-0.148
アフターアワーズ：
1.43
-0.01
-0.69%
Theratechnologies Inc (THTX) 最新ニュース
Theratechnologies (TSE:TH) Stock Passes Above 50-Day Moving AverageShould You Sell? - MarketBeat
Theratechnologies (NASDAQ:THTX) Shares Down 0.6%Time to Sell? - MarketBeat
Theratechnologies (NASDAQ:THTX) Shares Down 0.6% – Time to Sell? - Defense World
Theratechnologies (NASDAQ:THTX) Trading Down 0.6% – Time to Sell? - Defense World
Theratechnologies (TSE:TH) Stock Price Crosses Above 50-Day Moving AverageShould You Sell? - MarketBeat
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering - GlobeNewswire Inc.
Impending Shortage of Theratechnologies’ EGRIFTA SV® Amid Manufacturing Shutdown - TipRanks
Theratechnologies issues update on Egrifta SV shortage (THTX:NASDAQ) - Seeking Alpha
Theratechnologies Warns of Upcoming Shortage for HIV-Induced Stomach Fat Treatment - MarketWatch
Theratechnologies Provides Update on EGRIFTA SV® Supply - GlobeNewswire
Theratechnologies (TSE:TH) Reaches New 52-Week HighWhat's Next? - MarketBeat
Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update - MarketBeat
Theratechnologies (TSE:TH) Stock Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Theratechnologies expands rare disease portfolio with Ionis partnership - MSN
Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV® - TipRanks
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment - The Manila Times
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® ... - Russellville Courier
Theratechnologies Seeks FDA Approval for EGRIFTA SV® Manufacturing Changes Amid Supply Concerns - StockTitan
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Closing Bell: Theratechnologies Up On Wednesday (TH) - Barchart
Theratechnologies (TSE:TH) Stock Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Theratechnologies Secures Canadian Rights for Ionis RNA Medicines - TipRanks
Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Decreases By 44.0% - MarketBeat
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - Marketscreener.com
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - GlobeNewswire
Theratechnologies Awaits FDA Decision on New EGRIFTA Formulation, Sets March 2025 PDUFA Date - StockTitan
Theratechnologies Shows Promise in Ovarian Cancer Trial - TipRanks
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer - GlobeNewswire
Theratechnologies' Cancer Drug Shows Promise: Tumor Shrinkage in Phase 1b Trial - StockTitan
Deal Watch: GSK Extends Its Shingrix Alliance In China With Zhifei - News & Insights
Theratechnologies enters exclusive licensing agreement with Ionis - Yahoo Finance
Small caps to watch: This fintech stock has doubled this past year and analysts predict further record highs ahead - The Globe and Mail
Theratechnologies expands rare disease portfolio with Ionis partnership | 2024-12-04 | Investing News - Stockhouse Publishing
Theratechnologies Expands Portfolio with Ionis Deal - TipRanks
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen - The Bakersfield Californian
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada - GlobeNewswire
Theratechnologies Secures Exclusive Rights to Two Breakthrough Rare Disease Drugs in $22.75M Deal - StockTitan
EGRIFTA SV production restarts after FDA inspection - Investing.com India
Theratechnologies resumes production of EGRIFTA SV - MSN
EGRIFTA SV production restarts after FDA inspection By Investing.com - Investing.com Nigeria
Theratechnologies resumes production of Egrifta SV - Nasdaq
Theratechnologies Announces Resumed Production of EGRIFTA SV® - GlobeNewswire
Theratechnologies Inc. Announces Resume Production of EGRIFTA SV - Marketscreener.com
Theratechnologies secures up to $75M in new credit facilities - Yahoo Finance
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec - GlobeNewswire
Theratechnologies Secures $75M Credit Facility with Improved Terms, Freeing Up $19M Cash - StockTitan
Theratechnologies resubmits BLA for new tesamorelin formulation - MSN
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review - Marketscreener.com
Theratechnologies Resubmits Tesamorelin Application to FDA - TipRanks
Theratechnologies Resubmits FDA Application for Improved HIV Treatment Formulation | THTX Stock News - StockTitan
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):